ClinicalTrials.gg
CompletedNCT05778032ETABIOLPWSUpdated Nov 10, 2026

Biological Age Assessment in Adults With Prader-Willi Syndrome (ETABIOLPWS)

An observational study in Prader-Willi Syndrome, sponsored by Istituto Auxologico Italiano. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the study is to compare, in a cohort of obese subjects with PWS hospitalized at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy, the age acceleration calculated at study entry (T0) with the age acceleration measured at the end of a 3-week multidisciplinary metabolic rehabilitation program (T1).

Secondary objectives are to correlate the biological age with the anthropometric characteristics (with particular reference to the body composition), the glycometabolic picture, the main parameters and cardiovascular risk factors, the therapy (previous and concomitant) with rhGH and the cognitive function (mainly, the IQ).

Read the detailed description

Methods Thirty adults affected by clinically diagnosed and genetically confirmed PWS are recruited, regardless of the treatment (previous or concomitant) with rhGH (F/M = 15/15; age: ≥ 18 years; BMI > 35 kg/m2), hospitalized for a period of integrated multidisciplinary metabolic rehabilitation at the Division of Auxology, Istituto Auxologico Italiano, Piancavallo (VB), Italy.

After verifying the inclusion criteria, clinical and anthropometric data will be collected, including the evaluation of body composition with bioimpedance analysis. Cognitive function will be assessed with a psychometric scale (Wechsler Adult Intelligence Scale).

Blood samples will be taken from each patient upon admission to the hospital (T0) and after 3 weeks of rehabilitation hospitalization (at the same time to reduce circadian variability) for the determination of the basal glycometabolic profile (glucose, insulin, HOMA-IR, glycated Hb , triglycerides, total cholesterol, LDL, HDL, and hsPCR), as well as circulating levels of leptin, IL-6, and TNF-α.

The samples taken will be used for DNA extraction. DNA methylation will be performed by treatment with sodium bisulphite and PCR-Pyrosequencing.

Biological age measurement Biological (epigenetic) age will be measured using the two algorithms of Zbiec-Piekarska (9) and Daunay (10), based on the level of DNA methylation in specific gene loci. To have an estimate of the epigenetic (biological) age that is independent of the chronological age, we will use a measure defined as age acceleration, from which, with statistical inference, we will calculate the age acceleration. To calculate it, a linear regression model with the chronological age as the independent variable and the epigenetic age as the dependent variable will be applied; the difference between the observed value and the one predicted by the model will constitute the age acceleration due to epigenetic effects. In the event that the epigenetic age is greater than the chronological age, the age acceleration will have a positive value expressed in years, negative if vice versa.

02

Conditions studied

  • Prader-Willi Syndrome

Keywords

  • Prader-Willi syndrome
  • Obesity
  • Biological age
  • Metabolic rehabilitation
03

In context

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

This study's enrollment of 24 is below the median of 51 across 36 observational studies indexed under Prader-Willi Syndrome.

Browse Prader-Willi Syndrome studies →

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with Prader-Willi syndrome with BMI > 35 kg/m2

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients with PWS, clinically diagnosed and genetically confirmed, regardless of rhGH treatment (previous or concomitant)
  • age: ≥ 18 years
  • > 35 kg/m2
  • hospitalization for integrated multidisciplinary metabolic rehabilitation program

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • \< 35 kg/m2
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
24 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherMultidisciplinary metabolic rehabilitation program

    Multidisciplinary metabolic rehabilitation program with a duration of 3 weeks

06

What researchers measure

Primary outcomes

  1. DNA methylation

    Change in level of DNA methylation

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

Secondary outcomes

  1. Glycometabolic profile: glucose

    Change in glycometabolic profile - glucose levels

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

  2. Glycometabolic profile: insulin

    Change in glycometabolic profile - insulin levels

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

  3. Body fat mass

    Change in body fat mass - bioimpedance analysis

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

  4. Body fat free mass

    Change in body fat free mass - bioimpedance analysis

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

  5. Body weight

    Change in body weight

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

  6. Body mass index

    Change in body mass index

    Time frame: Baseline and at the end of the rehabilitation program (21 days)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2022 to primary completion in Feb 2025, 32 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2025 → Feb 2025 and completion Dec 2025 → Feb 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2023
First posted
Mar 21, 2023
StartActual
May 25, 2022
Primary completionActual
Feb 22, 2025was Dec 2025
CompletionActual
Feb 22, 2025was Dec 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Primary completion
Dec 31, 2025→Feb 22, 2025 (actual)
Nov 10, 2026
Study completion
Dec 31, 2025→Feb 22, 2025 (actual)
Nov 10, 2026
Enrollment
30→24
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Primary completion Dec 31, 2025→Feb 22, 2025 (now actual)
    Study completion Dec 31, 2025→Feb 22, 2025 (now actual)
    Enrollment 30→24
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05778032
Responsible party
Sponsor
First posted
Mar 21, 2023
Start date
May 25, 2022
Primary completion
Feb 22, 2025
Completion
Feb 22, 2025
Last update
Nov 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion